MedPath

Dynamic Coronary Roadmap for Contrast Reduction

Not Applicable
Completed
Conditions
Coronary Artery Disease
Registration Number
NCT04085614
Lead Sponsor
Philips Clinical & Medical Affairs Global
Brief Summary

The Dynamic Coronary Roadmap is a commercially available product developed by Philips Medical Systems, a Philips Healthcare company. Dynamic Coronary Roadmap is a software medical device intended to provide a real-time and dynamic angiographic roadmap of coronary arteries. The angiographic roadmap is automatically generated from previously acquired coronary angiograms during the same procedure. Dynamic Coronary Roadmap overlays the angiographic roadmap on live 2D fluoroscopic images, thereby assisting the physician in navigating devices, e.g. (guide) wires, catheters, through the coronary arteries.

This is a multi-center, prospective, unblinded, stratified 1:1 randomized controlled trial to assess whether using Dynamic Coronary Roadmap reduces the total iodinated contrast volume related to Percutaneous Coronary Intervention (PCI) compared to the control group without Dynamic Coronary Roadmap.

Detailed Description

Primary objective:

• To assess whether using Dynamic Coronary Roadmap reduces the total iodinated contrast volume related to Percutaneous Coronary Intervention (PCI) compared to the control group without Dynamic Coronary Roadmap.

Secondary objective:

• To assess the total number of contrast enhanced cine angiographic X-ray runs (angiograms) related to Percutaneous Coronary Intervention (PCI) in the Dynamic Coronary Roadmap and control group

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
371
Inclusion Criteria
  • Subject is undergoing Percutaneous Coronary Intervention (PCI) with a degree of complexity that anticipates the need for more than 25ml of iodinated contrast volume
  • Subject has signed informed consent
  • Subject is 18 years of age or older, or of legal age to give informed consent per state or national law
Exclusion Criteria
  • Subject undergoing emergency Percutaneous Coronary Intervention (PCI)
  • Subject with ST-segment Elevation Myocardial Infarction (STEMI)
  • Subject with Chronic Total Occlusion (CTO)
  • Subject undergoing PCI for isolated ostial disease of Left Main Coronary Artery (LMCA) or Right Coronary Artery (RCA)
  • Subject undergoing Percutaneous Coronary Intervention (PCI) with Optical Coherence Tomography (OCT) support
  • Subject undergoing Percutaneous Coronary Intervention (PCI) with rotational or orbital atherectomy
  • Subject with Chronic Kidney Disease (CKD) stage V (estimated Glomerular Filtration Rate (eGFR) < 15 ml/min/1.73 m^2)
  • Subject with contrast allergy that cannot be adequately pre-medicated
  • Subject participates in a potentially confounding drug or device trial during the course of the study.
  • Subject is under 18 years of age, or pregnant woman, or breast feeding woman, or meets an exclusion criteria according to national law

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Total Percutaneous Coronary Intervention (PCI) Iodinated Contrast VolumeDuring Percutaneous Coronary Intervention (PCI) procedure

Average total undiluted contrast volume (in ml, measured by an automatic contrast injector) per Percutaneous Coronary Intervention (PCI), where the start of the PCI is marked by the moment the interventional guiding catheter is positioned in a stable coronary position and the end of the PCI is marked by time of the last PCI check exposure run (angiogram).

Secondary Outcome Measures
NameTimeMethod
Number of AngiogramsDuring Percutaneous Coronary Intervention (PCI) procedure

Average total number of contrast enhanced cine angiographic X-ray runs (angiograms) per Percutaneous Coronary Intervention (PCI) (from start of PCI marked by the moment the interventional guiding catheter is positioned in a stable coronary position till the end of the PCI marked by the time of the last PCI check exposure run, i.e., angiogram) determined via visual assessment (e.g., on the Philips X-ray system).

Trial Locations

Locations (6)

University of Colorado Hospital

🇺🇸

Denver, Colorado, United States

Columbia University Medical Center/NYPH

🇺🇸

New York, New York, United States

Grand Hôpital de Charleroi Saint-Joseph

🇧🇪

Charleroi, Belgium

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

San Carlos Hospital

🇪🇸

Madrid, Spain

Fuenlabrada University Hospital

🇪🇸

Madrid, Spain

University of Colorado Hospital
🇺🇸Denver, Colorado, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.